BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10419479)

  • 1. Catalysis of ATP hydrolysis by two NH(2)-terminal fragments of yeast DNA topoisomerase II.
    Olland S; Wang JC
    J Biol Chem; 1999 Jul; 274(31):21688-94. PubMed ID: 10419479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization.
    Hu T; Sage H; Hsieh TS
    J Biol Chem; 2002 Feb; 277(8):5944-51. PubMed ID: 11850431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and mechanism of DNA topoisomerase II.
    Berger JM; Gamblin SJ; Harrison SC; Wang JC
    Nature; 1996 Jan; 379(6562):225-32. PubMed ID: 8538787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.
    Vaughn J; Huang S; Wessel I; Sorensen TK; Hsieh T; Jensen LH; Jensen PB; Sehested M; Nitiss JL
    J Biol Chem; 2005 Mar; 280(12):11920-9. PubMed ID: 15647268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradimerically tethered DNA topoisomerase II is catalytically active in DNA transport.
    Lindsley JE
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2975-80. PubMed ID: 8610153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II.
    Lindsley JE; Wang JC
    J Biol Chem; 1993 Apr; 268(11):8096-104. PubMed ID: 8385137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human topoisomerase II alpha heterodimer with only one ATP binding site can go through successive catalytic cycles.
    Skouboe C; Bjergbaek L; Oestergaard VH; Larsen MK; Knudsen BR; Andersen AH
    J Biol Chem; 2003 Feb; 278(8):5768-74. PubMed ID: 12480934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Communication between the ATPase and cleavage/religation domains of human topoisomerase IIalpha.
    Bjergbaek L; Kingma P; Nielsen IS; Wang Y; Westergaard O; Osheroff N; Andersen AH
    J Biol Chem; 2000 Apr; 275(17):13041-8. PubMed ID: 10777608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II.
    Caron PR; Watt P; Wang JC
    Mol Cell Biol; 1994 May; 14(5):3197-207. PubMed ID: 8164675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIbeta: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability.
    West KL; Turnbull RM; Willmore E; Lakey JH; Austin CA
    Nucleic Acids Res; 2002 Dec; 30(24):5416-24. PubMed ID: 12490710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissection of the contribution of individual domains to the ATPase mechanism of Hsp90.
    Wegele H; Muschler P; Bunck M; Reinstein J; Buchner J
    J Biol Chem; 2003 Oct; 278(41):39303-10. PubMed ID: 12890674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187.
    Classen S; Olland S; Berger JM
    Proc Natl Acad Sci U S A; 2003 Sep; 100(19):10629-34. PubMed ID: 12963818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA dependence of the ATPase activity of human DNA topoisomerase IIalpha.
    Hammonds TR; Maxwell A
    J Biol Chem; 1997 Dec; 272(51):32696-703. PubMed ID: 9405488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193.
    Morris SK; Baird CL; Lindsley JE
    J Biol Chem; 2000 Jan; 275(4):2613-8. PubMed ID: 10644721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.
    Sengupta T; Mukherjee M; Das A; Mandal C; Das R; Mukherjee T; Majumder HK
    Biochem J; 2005 Sep; 390(Pt 2):419-26. PubMed ID: 15901238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-terminal domain of human topoisomerase IIalpha is a DNA-dependent ATPase.
    Gardiner LP; Roper DI; Hammonds TR; Maxwell A
    Biochemistry; 1998 Dec; 37(48):16997-7004. PubMed ID: 9836594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) release.
    Baird CL; Gordon MS; Andrenyak DM; Marecek JF; Lindsley JE
    J Biol Chem; 2001 Jul; 276(30):27893-8. PubMed ID: 11353771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimerization of Escherichia coli DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center.
    Brino L; Urzhumtsev A; Mousli M; Bronner C; Mitschler A; Oudet P; Moras D
    J Biol Chem; 2000 Mar; 275(13):9468-75. PubMed ID: 10734094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.